<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03911128</url>
  </required_header>
  <id_info>
    <org_study_id>ALLTogether1 pilot</org_study_id>
    <nct_id>NCT03911128</nct_id>
  </id_info>
  <brief_title>A Treatment Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia</brief_title>
  <official_title>A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (1-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL): a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mats Heyman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Society for Pediatric Hematology and Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Swedish Childhood Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NordForsk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pilot study collects the experience of previously successful treatment of children and
      young adults, with ALL from a number of well-renowned study groups into a new platform
      protocol, which is both a comprehensive system for stratification and treatment of ALL in
      this age-group as well as the basis for several randomised trials included in the
      study-design.

      The pilot study will be implemented as a master protocol without study specific
      interventions, thus as an observational study. The pilot will run approximately one year
      before the start of the master protocol including interventions and is crucial to optimise
      registration systems, collaborations with vendors, logistics and data-checks before starting
      the main study.

      The study only includes &quot;standard of care&quot; treatment of the master protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aims of the ALLTogether study are to improve survival and quality of survival for
      children and young adults with ALL. ALL in young people has excellent outcome with &gt;90%
      survival in children and about 75% in young adults. However, patients still die of disease -
      after relapse as a result of under-treatment.

      Furthermore, a considerable fraction of younger patients are over-treated: All patients risk
      treatment-related death and some suffer long-term side-effects or secondary cancer. The rates
      of death from disease and death from therapy are almost the same for children. To show
      improvement with such good survival, large populations are needed.

      Study groups from the five Nordic countries, Estonia and Lithuania (NOPHO), the UK (UKALL),
      the Netherlands (DCOG), Germany (COALL), Belgium (BSPHO), Ireland (SHOP) and France (SFCE)
      have designed a common treatment protocol as new standard of care for children and young
      adults with ALL. The risk-stratification is based on a novel, personalised algorithm using
      clinical characteristics, genetic changes in the leukaemia and response to therapy.

      The protocol will, based on a personalised risk-approach, define a platform for diagnosis and
      treatment onto which randomized as well as non-randomised interventions and translational
      studies can be added.

      High-risk B-lineage patients may be stratified to Chimeric Antigen Receptor T-cell (CAR-T)
      therapy as an alternative to high-risk blocks and stem-cell transplant to reduce the
      side-effects.

      Translational and other therapy-related research will be promoted by the common master
      protocol.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2019</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS) compared to historical controls</measure>
    <time_frame>5 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS) compared to historical controls</measure>
    <time_frame>5 year</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">235</enrollment>
  <condition>Leukemia, Acute Lymphoblastic</condition>
  <arm_group>
    <arm_group_label>Participants with newly diagnosed ALL</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>Observational study - no intervention</description>
    <arm_group_label>Participants with newly diagnosed ALL</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Blood/blood plasma

        -  Cerebrospinal fluid

        -  Bone marrow
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants 1-45 years with newly diagnosed acute lymphoblastic leukaemia. The protocol
        has no gender-bias. The total estimated recruitment in the pilot study is 235 participants.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants newly diagnosed with T-lineage or precursor-B (BCP) ALL. Participants
             with mature B-ALL (Surface Ig positive) or ambiguous lineage acute leukaemia /mixed
             phenotype acute leukaemia (ALAL/MPAL) are not eligible for inclusion, but ALAL/MPAL
             participants may be treated according to the protocol therapy as standard of care at
             the discretion of the treating physician and after consultation with the national PI.

          -  Age ≥ 365 days and &lt; 46 years (one day before 46th birthday) at the time of diagnosis.

          -  Informed consent signed by the participant and/or parents/legal guardians according to
             country-specific age-related guidelines
             (http://www.ema.europa.eu/docs/en_GB/document_library/Other/2015/12/WC500199 234.pdf
             ).

          -  The ALL diagnosis should be confirmed by an accredited laboratory at a participating
             paediatric oncology or adult haematology centre.

          -  The participant should be diagnosed and treated at a participating paediatric oncology
             or adult haematology centre in the participating countries.

          -  The participant should be a resident in one of the participating countries on a
             permanent basis or should intend to settle in a participating country, for instance by
             an application for asylum. Participants who are visiting the country as tourists
             should not be included. However, returning expatriates with primary diagnosis abroad
             may be included if no treatment has been administered and the diagnostic procedures
             are repeated at a participating centre.

          -  All female participants of childbearing potential have to have a negative pregnancy
             test within 2 weeks prior to the start of treatment.

        Exclusion Criteria:

          -  Age &lt; 365 days at diagnosis (infant ALL) or &gt;45 years at diagnosis.

          -  Participants with a previous malignant diagnosis (ALL as a second malignant neoplasm -
             SMN).

          -  Relapse of ALL.

          -  Participants with mature B-ALL (as defined by Surface Ig positivity or documented
             presence of one of the t(8;14), t(2;8), t(8;22) translocations and breakpoint as in
             B-ALL).

          -  Participants with Ph-positive ALL (documented presence of t(9;22)(q34;q11) and/or of
             the BCR/ABL fusion transcript). These participants will be transferred to an adequate
             trial for t(9;22) if available.

          -  ALL prone syndromes (e.g. Li-Fraumeni syndrome, germline ETV6 mutation), except for
             Down syndrome. Exploration for such ALL prone syndromes is not mandatory.

          -  Treatment with systemic corticosteroids for more than one week and/or other
             chemotherapeutic agents in a 4-week interval prior to diagnosis (pre-treatment).

          -  Pre-existing contraindications for treatment according to (parts of) the ALLTogether
             protocol (constitutional or acquired disease prior to the diagnosis of ALL preventing
             adequate treatment).

          -  Any other disease or condition, as determined by the investigator, which could
             interfere with the participation in the study according to the study protocol, or with
             the ability of the participants to cooperate and comply with the study procedures.

          -  Female participants who are pregnant at the time of diagnosis.

          -  Male or female participants who are sexually active and are unwilling to use adequate
             contraception during therapy.

          -  Female participants, who are breast-feeding.

          -  Essential data missing (in consultation with the protocol chair).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mats Heyman, M.D. PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mats Heyman, M.D. PhD</last_name>
    <phone>+46 8 517 704 07</phone>
    <email>mats.heyman@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Flood, M.Sc.</last_name>
    <phone>+46 70 321 49 22</phone>
    <email>karin.flood@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital, Dept of Paediatrics</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruta Tuckuviene, M.D.</last_name>
      <email>rt@rn.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mette Skov Holm, M.D.</last_name>
      <email>mettehlm@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital, Child and Adolescent Health</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgitte Klug Albertsen, M.D.</last_name>
      <email>biralber@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Dept of Haematology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrik Malthe Overgaard, M.D.</last_name>
      <email>ulrik.malthe.overgaard@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Dept of Paediatrics</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kjeld Schmiegelow, M.D.</last_name>
      <email>kschmiegelow@rh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital, Dept of Paediatrics</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peder Skov Wehner, M.D.</last_name>
      <email>peder.skov.wehner@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital, Dept of Haematology</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulla Wartiovaara-Kautto, M.D.</last_name>
      <email>ulla.wartiovaara-kautto@hus.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital, Dept of Paediatrics</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mervi Taskinen, M.D.</last_name>
      <email>mervi.taskinen@hus.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital, Dept of Haematology</name>
      <address>
        <city>Kuopio</city>
        <zip>70029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marja Pyörälä, M.D.</last_name>
      <email>Marja.Pyorala@kuh.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital, Dept of Paediatrics</name>
      <address>
        <city>Kuopio</city>
        <zip>70029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaisa Vepsäläinen, M.D.</last_name>
      <email>kaisa.vepsalainen@kuh.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital, Dept of Haematology, Dept of Medicine</name>
      <address>
        <city>Oulu</city>
        <zip>90029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timo Siitonen, M.D.</last_name>
      <email>Timo.Siitonen@ppshp.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital, Dept of Paediatrics</name>
      <address>
        <city>Oulu</city>
        <zip>90029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riitta Niinimäki, M.D.</last_name>
      <email>riitta.niinimaki@ppshp.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital, Dept of Haematology</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johanna Rimpilainen, M.D.</last_name>
      <email>Johanna.Rimpilainen@pshp.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital, Dept of Paediatrics</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olli Lohi, M.D.</last_name>
      <email>olli.lohi@staff.uta.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital, Clinical Haematology and Stem Cell Transplantation Unit</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Urpu Salmenniemi, M.D.</last_name>
      <email>urpu.salmenniemi@tyks.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital, Dept of Paediatrics</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Päivi Lähteenmäki, M.D.</last_name>
      <email>Paivi.Maria.Lahteenmaki@tyks.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Landspitali University Hospital, Children's Hospital</name>
      <address>
        <city>Reykjavík</city>
        <zip>101</zip>
        <country>Iceland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ólafur G. Jónsson, M.D.</last_name>
      <email>olafurgi@landspitali.is</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Affiliate of Vilnius University Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Goda Vaitkeviciene, M.D.</last_name>
      <email>goda.vaitkeviciene@vuvl.lt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laimonas Griskevicius, M.D.</last_name>
      <email>laimonas.griskevicius@santa.lt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital, Dept of Haematology</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Øystein Halvorsen, M.D.</last_name>
      <email>oystein.halvorsen@helse-bergen.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital, Dept of Paediatrics</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorota Wojcik, M.D.</last_name>
      <email>dorota.malgorzata.wojcik@helse-bergen.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Dept of Haematology</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilde Skuterud Wik, M.D.</last_name>
      <email>UXZWHI@ous-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Dept of paediatric haemato- and oncology</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inga Maria Johannsdottir, M.D.</last_name>
      <email>ijohanns@ous-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital, Dept of Haematology</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Meyer, M.D.</last_name>
      <email>peter.albert.meyer@sus.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital North Norway, Dept of Haematology</name>
      <address>
        <city>Tromsø</city>
        <zip>9019</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Vik, M.D.</last_name>
      <email>anders.vik@unn.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway, Dept of Paediatrics</name>
      <address>
        <city>Tromsø</city>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trond Flægstad, M.D.</last_name>
      <email>Trond.Flaegstad@unn.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Olavs University Hospital, Dept of Paediatrics</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bendik Lund, M.D.</last_name>
      <email>bendik.lund@ntnu.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Olavs University Hospital, Dept of Haematology</name>
      <address>
        <city>Trondheim</city>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petter Quist-Paulsen, M.D.</last_name>
      <email>petter.quist-paulsen@stolav.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital, Section for Haematology and coagulation</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Hulegårdh, M.D.</last_name>
      <email>erik.hulegardh@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital, Dept of Paediatric Haematology and Oncology</name>
      <address>
        <city>Gothenburg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas Abrahamsson, M.D.</last_name>
      <email>jonas.abrahamsson@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital, Dept of Haematology</name>
      <address>
        <city>Linköping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Ahlberg, M.D.</last_name>
      <email>lucia.ahlberg@regionostergotland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital, Dept of Paediatrics</name>
      <address>
        <city>Linköping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hartmut Vogt, M.D.</last_name>
      <email>hartmut.vogt@regionostergotland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital, Dept of Haematology</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Tomaszewska-Toporska, M.D.</last_name>
      <email>Beata.Tomaszewska-Toporska@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital, Dept of Paediatrics</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Castor, M.D.</last_name>
      <email>anders.castor@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital, Dept of Paediatric Oncology and Haematology</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Malmros, M.D.</last_name>
      <email>johan.malmros@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital, Patient area Haematology</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Joelsson, M.D.</last_name>
      <email>joel.joelsson@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norrland University Hospital, Dept of Haematology</name>
      <address>
        <city>Umeå</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Izarra, M.D.</last_name>
      <email>Antonio.Izarra.Santamaria@vll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norrland University Hospital, Dept of Paediatrics</name>
      <address>
        <city>Umeå</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrika Norén Nyström, M.D.</last_name>
      <email>ulrika.noren-nystrom@umu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital, Dept of Haematology</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helene Hallböök, M.D.</last_name>
      <email>helene.hallbook@medsci.uu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital, Dept of Paediatric Haematology and Oncology</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arja Harila-Saari, M.D.</last_name>
      <email>arja.harila-saari@kbh.uu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital, Section for Haematology</name>
      <address>
        <city>Örebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Kozlowski, M.D.</last_name>
      <email>piotr.kozlowski@orebroll.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Iceland</country>
    <country>Lithuania</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Toft N, Birgens H, Abrahamsson J, Griškevičius L, Hallböök H, Heyman M, Klausen TW, Jónsson ÓG, Palk K, Pruunsild K, Quist-Paulsen P, Vaitkeviciene G, Vettenranta K, Åsberg A, Frandsen TL, Marquart HV, Madsen HO, Norén-Nyström U, Schmiegelow K. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018 Mar;32(3):606-615. doi: 10.1038/leu.2017.265. Epub 2017 Aug 18.</citation>
    <PMID>28819280</PMID>
  </reference>
  <reference>
    <citation>Schramm F, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, Imschweiler T, Christiansen H, Faber J, Feuchtinger T, Schmid I, Beron G, Horstmann MA, Escherich G. Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09. Leuk Lymphoma. 2019 Jan;60(1):60-68. doi: 10.1080/10428194.2018.1473575. Epub 2018 Jul 3.</citation>
    <PMID>29966458</PMID>
  </reference>
  <reference>
    <citation>Mondelaers V, Suciu S, De Moerloose B, Ferster A, Mazingue F, Plat G, Yakouben K, Uyttebroeck A, Lutz P, Costa V, Sirvent N, Plouvier E, Munzer M, Poirée M, Minckes O, Millot F, Plantaz D, Maes P, Hoyoux C, Cavé H, Rohrlich P, Bertrand Y, Benoit Y; Children–s Leukemia Group (CLG) of the European Organization for Research and Treatment of Cancer (EORTC). Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951. Haematologica. 2017 Oct;102(10):1727-1738. doi: 10.3324/haematol.2017.165845. Epub 2017 Jul 27.</citation>
    <PMID>28751566</PMID>
  </reference>
  <reference>
    <citation>Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, Rowntree C, Richards S. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013 Mar;14(3):199-209. doi: 10.1016/S1470-2045(12)70600-9. Epub 2013 Feb 7.</citation>
    <PMID>23395119</PMID>
  </reference>
  <reference>
    <citation>Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, Egeler RM, Hoogerbrugge P, Kaspers G, Van der Schoot E, De Haas V, Van Dongen J. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol. 2016 Aug 1;34(22):2591-601. doi: 10.1200/JCO.2015.64.6364. Epub 2016 Jun 6.</citation>
    <PMID>27269950</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Mats Heyman</investigator_full_name>
    <investigator_title>MD, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Acute Lymphoblastic</keyword>
  <keyword>ALL</keyword>
  <keyword>ALLTogether</keyword>
  <keyword>Leukaemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Individual participant data will be entered into the study database. The data will only be used to inform the coming main study regarding safety and overall outcomes of the master protocol.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

